{"id":2515,"date":"2025-02-06T10:27:47","date_gmt":"2025-02-06T10:27:47","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solutions&p=2515"},"modified":"2025-06-01T14:55:54","modified_gmt":"2025-06-01T14:55:54","slug":"translational-models","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/translational-models\/","title":{"rendered":"Translational Models"},"content":{"rendered":"
\n
\n
\n

Translational models for pre-clinical and clinical studies<\/h2>\n

Tissue-based tools drive drug development in both pre-clinical and clinical phases to improve the success rate of drug development. Accordingly, the FDA and EMA have expressed the view that biomarker-based drug development strategies, in combination with translational research, may offer a biology-focused approach that reduces time and cost and increases the overall likelihood of success.<\/p>\n

\n \n Get in touch with our team \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n <\/div>\n<\/section>\n\n\n\n\n
\n \n
\n
\n
\n
\n

Strategic drug development in translational studies<\/h2>\n \n\n <\/div>\n
\n

A drug development route for success is key but often challenging and full of uncertainties. Strategies that can increase the likelihood of success are vital. The FDA and EMA recognize that biomarker-based drug development strategies, in combination with translation research, could be the solution. This approach offers a biology-focused pathway that not only reduces time and cost but also enhances the overall likelihood of success.<\/p>\n

Nordic Bioscience combines innovative translational models with the\u00a0ProteinFingerPrint Technology\u2122<\/a>\u00a0to translate findings effectively. This is facilitated by utilizing the same biomarkers across different clinical stages of development creating a link between the preclinical model and the clinic. This strategically selected development route greatly enhances the efficiency of drug development pipelines.<\/p>\n

In essence, the integration of biomarker-based drug development strategies in translational research not only accelerates the progression of therapeutics but also increases the likelihood of success. Through advanced translational models in combination with the ProteinFingerPrint\u2122 biomarkers<\/a>, Nordic Bioscience contributes significantly to the optimization of decision-making processes in clinical development, ultimately ensuring better treatments for the patients.<\/p>\n <\/div>\n

\n

We offer translational biomarker services in various indications<\/h3>\n